Conditions: Alzheimer Disease
Keywords: antibody immunotherapy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 79
Healthy volunteers: no

Brief summary:
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.

Detailed description:

Arms:
arm 1: 5 mg/week arm 2: 10 mg/week arm 3: Placebo

Interventions: intervention 1: bapineuzumab intervention 2: bapineuzumab intervention 3: placebo
Intervention descriptions: intervention 1: 5 mg bapineuzumab subcutaneous injection once per week for 6 months intervention 2: 10 mg bapineuzumab subcutaneous injection once per week for 6 months intervention 3: Placebo subcutaneous injection once per week for 6 months

Protocol document: